Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

Published:2017-11-03 Issue:1 Volume:33 Page:1-8
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Fischer Tim¹,Najjar Abdulkarim¹,Totzke Frank²,Schächtele Christoph²,Sippl Wolfgang¹,Ritter Christoph³,Hilgeroth Andreas¹

Affiliation:

1. Department of Pharmaceutical Chemistry, Institute of Pharmacy, Martin Luther University, Halle, Germany;

2. ProQinase GmbH Freiburg, Freiburg, Germany;

3. Department of Clinical Pharmacy, Institute of Pharmacy, University of Greifswald, Greifswald, Germany

Funder

German Research Foundation

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://tandfonline.com/doi/pdf/10.1080/14756366.2017.1370583

Reference26 articles.

1. Deregulation of cell signaling in cancer

2. Protein kinases as targets for cancer treatment

3. The molecular basis of targeting protein kinases in cancer therapeutics

4. Targeting cancer with small molecule kinase inhibitors

5. Features of Selective Kinase Inhibitors

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TGF-β-Based Therapies for Treating Ocular Surface Disorders;Cells;2024-06-26

2. Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review;International Journal of Biological Macromolecules;2023-12

3. Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors;ACS Omega;2023-05-23

4. Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors;Journal of Enzyme Inhibition and Medicinal Chemistry;2022-09-29

5. Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure;Expert Opinion on Drug Discovery;2022-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3